Ramses Erdtmann

Mr. Rainer M.
Erdtmann is a President, Chief Operating Officer & Director at Biomea Fusion, Inc., a Managing Member at Point Sur Investors LLC, a Managing Director at Oxygen Investments LLC and a President at Biomea Health LLC.
He is on the Board of Directors at Biomea Fusion, Inc. Prior to forming Point Sur Investors, from 2008-2016, Mr. Erdtmann was with Pharmacyclics, Inc., a Nasdaq-listed biotech company.
He began as Vice President, Finance & Administration, Corporate Secretary and acted as the Principal Financial and Accounting Officer.
In that capacity he was responsible for accounting, SEC reporting, audits, and investor relations.
He built and had operational responsibility for Finance, IT, HR, Legal, Facilities, and Events.
He later served as Executive Vice President of Corporate Affairs including Corporate Communications.
Additionally, he structured and administered the international revenue for Pharmacyclics into a swiss-based subsidiary.
He also actively participated in the final execution of key corporate milestones for Pharmacyclics, among them the Collaboration Agreement with J&J in 2011 (value $1.0 Billion) and the merger agreement with AbbVie in 2015 (value $21 Billion).
Prior to Pharmacyclics, he worked as an asset manager and investment banker, representing European and US institutional investors, family offices and high net worth investors.
He began his career at Commerzbank, Germany, where he was an investment banker and portfolio manager for institutional international accounts.
He earned the Diplom Kaufmann degree, with honors, in Finance and Banking from the Westfaelische Wilhelms Universitaet Muenster, Germany.